Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

ACTIVE NOT RECRUITING Phase 4

A Study to Evaluate the Safety and Effectiveness of JUVÉDERM Products in Adult Participants for the Change of Their Overall Facial Appearance

NCT07186595 · View on ClinicalTrials.gov ↗

Study Summary

The purpose of this study is to evaluate the safety and effectiveness of JUVÉDERM products in adults seeking improvement in facial volume and/or skin quality.

Conditions Studied

Interventions

  • DEVICE JUVÉDERM VOLUX XC
  • DEVICE JUVÉDERM VOLUMA XC
  • DEVICE JUVÉDERM VOLBELLA XC
  • DEVICE JUVÉDERM VOLLURE XC
  • DEVICE SKINVIVE by JUVÉDERM

Study Locations (10)

California

  • Kian Aesthetic Institute /ID# 277045 — Los Angeles
  • West Dermatology La Jolla /ID# 277034 — San Diego
  • Pacific Clinical Innovations /ID# 277026 — Vista

Louisiana

  • H&H Research, LLC /ID# 277084 — Metairie
  • DelRicht Research - New Orleans 308 /ID# 277039 — New Orleans

Florida

  • Skin Research Institute LLC /ID# 277038 — Coral Gables

Georgia

  • Monarch Plastic Surgery and Skin Renewal Center /ID# 278182 — Atlanta

Illinois

  • Advanced Dermatology - Lincolnshire /ID# 277036 — Lincolnshire

Texas

  • Bellaire Dermatology Associates /ID# 278180 — Bellaire

Virginia

  • SkinDC /ID# 277062 — Arlington

Trial Details

FieldValue
Enrollment Target 75 participants
Start Date 2025-09-25
Est. Completion 2026-08
Phase Phase 4

Sponsor

AbbVie

603 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07186595

The ClinicalTrials.gov registry entry for NCT07186595 describes a study currently listed as active not recruiting. It is categorized as Phase 4, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 603 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Mid Face Volume Deficit appearing as the primary indexed condition, and to 5 interventions — of which JUVÉDERM VOLUX XC is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT07186595 reports 10 study locations spanning 7 distinct geographic areas — top geographies include California, Louisiana, Florida. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT07186595 about?

NCT07186595 is a clinical study titled "A Study to Evaluate the Safety and Effectiveness of JUVÉDERM Products in Adult Participants for the Change of Their Overall Facial Appearance". The purpose of this study is to evaluate the safety and effectiveness of JUVÉDERM products in adults seeking improvement in facial volume and/or skin quality.

What is the current status of trial NCT07186595?

This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 75 participants. The study started on 2025-09-25. Estimated completion is 2026-08.

What conditions does trial NCT07186595 study?

This clinical trial studies the following conditions: Mid Face Volume Deficit. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT07186595?

The interventions under investigation include: JUVÉDERM VOLUX XC (DEVICE), JUVÉDERM VOLUMA XC (DEVICE), JUVÉDERM VOLBELLA XC (DEVICE), JUVÉDERM VOLLURE XC (DEVICE), SKINVIVE by JUVÉDERM (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT07186595?

This trial is sponsored by AbbVie, which has 603 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT07186595 being conducted?

This trial has 10 study locations across California, Florida, Georgia, Illinois, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial